Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.

Purpose Cholesterol-lowering medication (CLM) has been reported to have a role in preventing breast cancer recurrence. CLM may attenuate signaling through the estrogen receptor by reducing levels of the estrogenic cholesterol metabolite 27-hydroxycholesterol. The impact of endocrine treatment on cholesterol levels and hypercholesterolemia per se may counteract the intended effect of aromatase inhibitors. Patients and Methods The Breast International Group (BIG) conducted a randomized, phase III, double-blind trial, BIG 1-98, which enrolled 8,010 postmenopausal women with early-stage, hormone receptor-positive invasive breast cancer from 1998 to 2003. Systemic levels of total cholesterol and use of CLM were measured at study entry and every 6 months up to 5.5 years. Cumulative incidence functions were used to describe the initiation of CLM in the presence of competing risks. Marginal structural Cox proportional hazards modeling investigated the relationships between initiation of CLM during endocrine therapy and outcome. Three time-to-event end points were considered: disease-free-survival, breast cancer-free interval, and distant recurrence-free interval. Results Cholesterol levels were reduced during tamoxifen therapy. Of 789 patients who initiated CLM during endocrine therapy, the majority came from the letrozole monotherapy arm (n = 318), followed by sequential tamoxifen-letrozole (n = 189), letrozole-tamoxifen (n = 176), and tamoxifen monotherapy (n = 106). Initiation of CLM during endocrine therapy was related to improved disease-free-survival (hazard ratio [HR], 0.79; 95% CI, 0.66 to 0.95; P = .01), breast cancer-free interval (HR, 0.76; 95% CI, 0.60 to 0.97; P = .02), and distant recurrence-free interval (HR, 0.74; 95% CI, 0.56 to 0.97; P = .03). Conclusion Cholesterol-lowering medication during adjuvant endocrine therapy may have a role in preventing breast cancer recurrence in hormone receptor-positive early-stage breast cancer. We recommend that these observational results be addressed in prospective randomized trials.

[1]  N. Boyd,et al.  Serum lipids, lipoproteins, and risk of breast cancer: a nested case-control study using multiple time points. , 2015, Journal of the National Cancer Institute.

[2]  I. Hedenfalk,et al.  Global Transcriptional Changes Following Statin Treatment in Breast Cancer , 2015, Clinical Cancer Research.

[3]  J. Manson,et al.  Statins and breast cancer stage and mortality in the Women’s Health Initiative , 2015, Cancer Causes & Control.

[4]  C. Cardwell,et al.  Statin Use After Diagnosis of Breast Cancer and Survival: A Population-based Cohort Study , 2015, Epidemiology.

[5]  E. Nelson,et al.  Cholesterol and breast cancer pathophysiology , 2014, Trends in Endocrinology & Metabolism.

[6]  C.-Y. Chang,et al.  The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer , 2014, Climacteric : the journal of the International Menopause Society.

[7]  H. Vainio,et al.  Statin Use and Breast Cancer Survival: A Nationwide Cohort Study from Finland , 2014, PloS one.

[8]  T. Ahern,et al.  Statins and breast cancer prognosis: evidence and opportunities. , 2014, The Lancet. Oncology.

[9]  Vered Stearns,et al.  Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[11]  D. Buist,et al.  Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer , 2014, Breast Cancer Research and Treatment.

[12]  J. Gustafsson,et al.  On estrogen, cholesterol metabolism, and breast cancer. , 2014, The New England journal of medicine.

[13]  S. Kuo,et al.  Adjuvant Tamoxifen Influences the Lipid Profile in Breast Cancer Patients , 2014, Breast Care.

[14]  Jeff S. Jasper,et al.  27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology , 2013, Science.

[15]  L. Girard,et al.  27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. , 2013, Cell reports.

[16]  J. Chang-Claude,et al.  Mortality and Recurrence Risk in Relation to the Use of Lipid-Lowering Drugs in a Prospective Breast Cancer Patient Cohort , 2013, PloS one.

[17]  A. Chattopadhyay,et al.  Cholesterol Biosynthesis and Homeostasis in Regulation of the Cell Cycle , 2013, PloS one.

[18]  N. Loman,et al.  Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial , 2013, Breast Cancer Research and Treatment.

[19]  J. W. Clendening,et al.  Targeting tumor cell metabolism with statins , 2012, Oncogene.

[20]  S. Bojesen,et al.  Statin use and reduced cancer-related mortality. , 2012, The New England journal of medicine.

[21]  A. Giobbie-Hurder,et al.  Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer , 2011, Breast Cancer Research.

[22]  A. Giobbie-Hurder,et al.  Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer , 2009, Clinical trials.

[23]  Yun-Mi Song,et al.  Serum total cholesterol and the risk of breast cancer in postmenopausal Korean women , 2009, Cancer Causes & Control.

[24]  F. Pontén,et al.  Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer , 2008, Breast Cancer Research.

[25]  F. Pontén,et al.  HMG‐CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors , 2008, International journal of cancer.

[26]  L. Habel,et al.  Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors , 2008, Breast Cancer Research and Treatment.

[27]  J. Forbes,et al.  Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Petricoin,et al.  Breast cancer growth prevention by statins. , 2006, Cancer research.

[29]  G. Hortobagyi,et al.  Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. , 2006, Breast.

[30]  J. Forbes,et al.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.

[31]  M. Haberal,et al.  Hypercholesterolemia impairs angiogenesis in patients with breast carcinoma and, therefore, lowers the risk of metastases. , 2004, American journal of clinical pathology.

[32]  F. Appelbaum,et al.  Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. , 2004, Blood.

[33]  J. Liao.  Isoprenoids as mediators of the biological effects of statins. , 2002, The Journal of clinical investigation.

[34]  M. Elisaf,et al.  Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. , 2001, European journal of cancer.

[35]  J. Robins,et al.  Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. , 2000, Epidemiology.

[36]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[37]  N. Boyd,et al.  RE: Serum Lipids, Lipoproteins, and Risk of Breast Cancer: A Nested Case-Control Study Using Multiple Time Points. , 2016, Journal of the National Cancer Institute.

[38]  Dorota H. Sendorek,et al.  Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells , 2013, Breast Cancer Research and Treatment.

[39]  W. Tereffe.  Statin prescriptions and breast cancer recurrence risk: A Danish nationwide prospective cohort study , 2012 .

[40]  L. Esserman,et al.  Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer , 2009, Breast Cancer Research and Treatment.